Rivastigmine (Exelon)

A carbamate-derived reversible CHOLINESTERASE INHIBITOR that is selective for the CENTRAL NERVOUS SYSTEM and is used for the treatment of DEMENTIA in ALZHEIMER DISEASE and PARKINSON DISEASE.

Also Known As:

Exelon; (S)-N-Ethyl-3-((1-dimethyl-amino)ethyl)-N-methylphenylcarbamate; ENA 713; ENA-713; Rivastigmine Hydrogen Tartrate; RivastigmineTartrate; SDZ ENA 713; 713, ENA; 713, SDZ ENA; ENA 713, SDZ; ENA713; Hydrogen Tartrate, Rivastigmine; Tartrate, Rivastigmine Hydrogen; Carbamic acid, ethylmethyl-, 3-(1-(dimethylamino)ethyl)phenyl ester, (S)-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1)

Networked: 1041 relevant articles (163 outcomes, 307 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Acyclic Acids
    - Carbamates: 945
      - Phenylcarbamates: 7
        Rivastigmine: 1041

Experts

1.	Meng, Xiangyi: 28 articles (05/2016 - 01/2008)
2.	Grossberg, George T: 20 articles (01/2021 - 01/2002)
3.	Lane, Roger: 20 articles (01/2010 - 01/2003)
4.	Farlow, Martin R: 18 articles (06/2015 - 09/2003)
5.	Olin, Jason T: 14 articles (04/2011 - 06/2007)
6.	Tekin, Sibel: 12 articles (04/2011 - 12/2004)
7.	Koumaras, Barbara: 12 articles (04/2010 - 06/2003)
8.	Emre, Murat: 10 articles (01/2014 - 12/2004)
9.	Bullock, Roger: 10 articles (08/2010 - 03/2002)
10.	Sadowsky, Carl H: 9 articles (06/2015 - 01/2005)

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease) 04/01/2015 - "The long-term safety, tolerability, and efficacy of high-dose 13.3 mg/24 h rivastigmine patch in severe Alzheimer disease was evaluated in a 24-week, open-label extension to the double-blind ACTION study. " 07/01/2009 - "A randomized controlled trial (n = 541) showed that, compared with placebo, rivastigmine (mean, 8.6 mg/d) significantly improved scores on 2 coprimary cognitive outcome scales in PDD, including the Alzheimer disease Cooperative Study-Clinician's Global Impression of Change. " 04/10/2015 - "Rivastigmine (6 to 12 mg daily orally or 9.5 mg daily transdermally) appears to be beneficial for people with mild to moderate Alzheimer's disease. " 01/01/2015 - "Rivastigmine (6 to 12 mg daily orally or 9.5 mg daily transdermally) appears to be beneficial for people with mild to moderate Alzheimer's disease. " 04/15/2009 - "Rivastigmine appears to be beneficial for people with mild to moderate Alzheimer's disease. "
2.	Dementia (Dementias) 01/01/2021 - "The pharmacists of the dementia care team often intervened in the proper use of rivastigmine, which was found to be effective when increasing the dose. " 07/01/2012 - "Our study suggests that there are differences in the efficacy of Ginkgo biloba and rivastigmine in the treatment of Alzheimer's dementia. " 12/16/2000 - "Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study." 05/01/2000 - "The objective of this study was to assess the tolerability and efficacy of rivastigmine in a group of patients with probable dementia with Lewy bodies (DLB), using an open label study. " 07/01/2012 - "Efficacy of rivastigmine in comparison to ginkgo for treating Alzheimer's dementia."
3.	Cognitive Dysfunction 01/01/2007 - "The aim of the present study was to assess the long-term efficacy of rivastigmine on motor and cognitive impairment in HD patients. " 10/01/2017 - "Our aim was to study the effectiveness of rivastigmine prophylaxis on the incidence, severity, and risk factors for POD in older patients with cognitive impairment undergoing hip fracture surgery. " 09/28/2015 - "These preliminary results emphasize the need for detailed profiling of cognitive impairment when developing a research design to study the potential benefits of rivastigmine in the prevention or treatment of cognitive impairment in severely depressed patients treated with ECT. " 12/01/2009 - "The aim of the study is to evaluate the efficacy and safety of rivastigmine 3 mg/day over 12 weeks in patients with aneurysmal subarachnoid haemorrhage and persistent cognitive impairment. " 09/01/2008 - "The aim of this study was to evaluate the effect of rivastigmine in treating memory and cognitive dysfunction in MS. A single-center double-blind placebo-controlled randomized clinical trial conducted from October 2005 to February 2007. "
4.	Parkinson Disease (Parkinson's Disease) 11/17/2023 - "Embase, Medline, PsychINFO, Cochrane CENTRAL, NGLC, National Institute for Health and Care Excellence Evidence and medRxiv.org were searched for studies with terms relating to population (Parkinson's disease) and intervention (rivastigmine). " 03/01/2016 - "Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial." 12/03/2013 - "The ReSPonD trial--rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen." 11/01/2001 - "This open study assessed the ability of rivastigmine to treat the neuropsychiatric complications of advanced Parkinson's disease. " 11/17/2023 - "The effects of rivastigmine on neuropsychiatric symptoms in the early stages of Parkinson's disease: A systematic review."
5.	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 05/01/2005 - "Small open-label studies of patients with subcortical vascular dementia showed that rivastigmine improved attention, executive function, apathy and other behavioral deficits. " 05/31/2013 - " trial included 40 participants with subcortical vascular dementia (age range 40 to 90 years) with a mean mini-mental state examination (MMSE) score of 13.0 and 13.4 in the rivastigmine and placebo arms, respectively. " 09/01/2008 - "VantagE (Vascular Dementia trial studying Exelon) was a 24-week, multicentre, double-blind study. " 09/01/2008 - "Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study." 05/01/2005 - "Rivastigmine appears to be a promising agent in vascular dementia but its effects remain to be established in double-blind, placebo-controlled clinical trials."

Related Drugs and Biologics

1.	Donepezil (Aricept)
2.	Cholinesterase Inhibitors (Anticholinesterases)
3.	Galantamine (Galanthamine)
4.	Memantine (Namenda)
5.	Cholinergic Agents (Cholinergics)
6.	Rivastigmine (Exelon)
7.	tartaric acid (tartrate)
8.	Tacrine (Cognex)
9.	Trichlorfon (Metrifonate)
10.	Nootropic Agents (Nootropics)

Related Therapies and Procedures

1.	Therapeutics
2.	Transdermal Patch
3.	Activities of Daily Living (ADL)
4.	Home Nursing (Nursing, Home)
5.	Cutaneous Administration